Base de dados : LILACS Pesquisa : D08.811.913.696.620.682.725.500.500 [Categoria DeCS] Referências encontradas : 34 [refinar] Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 4

ir para página

1 / 34

LILACS

seleciona para imprimir Fotocópia Texto completo SciELO Brasil Texto completo Texto completo

Id: lil-654967 Autor: Giunta, Marina; Pucillo, Carlo. Título: BCR-ABL rearrangement and HLA antigens: a possible link to leukemia pathogenesis and immunotherapy Fonte: Rev. bras. hematol. hemoter;34(5):323-324, 2012. Idioma: en. Descritores: Leucemia/etiologia Proteínas de Fusão bcr-abl Antígenos HLA Imunoterapia Limites: Humanos Tipo de Publ: Comentário Responsável: BR408.1 - Biblioteca da Faculdade de Medicina - BFM

2 / 34

LILACS

seleciona para imprimir Fotocópia Texto completo SciELO Brasil Texto completo Texto completo

Id: lil-741874 Autor: Asinari, Mariana Beatriz; Zeballos, Maximiliano; Alicia, Sturich; Ricchi, Brenda Nidia; Basquiera, Ana Lisa. Título: A case of chronic myeloid leukemia with the m-bcr (p190) molecular rearrangement identifi ed during treatment Fonte: Rev. bras. hematol. hemoter;37(1):55-57, Jan-Feb/2015. Idioma: en. Descritores: Rearranjo Gênico Leucemia Mielogênica Crônica BCR-ABL Positiva Proteínas de Fusão bcr-abl Diabetes Mellitus Limites: Humanos Feminino Idoso Tipo de Publ: Relatos de Casos Responsável: BR408.1 - Biblioteca da Faculdade de Medicina - BFM

3 / 34

LILACS

seleciona para imprimir Fotocópia Texto completo SciELO Brasil Texto completo Texto completo

Id: biblio-898930 Autor: Vieira-Mion, Ana Lucia; Pereira, Noemi Farah; Funke, Vaneuza Araujo Moreira; Pasquini, Ricardo. Título: Molecular response to imatinib mesylate of Brazilian patients with chronic myeloid leukemia Fonte: Rev. bras. hematol. hemoter;39(3):210-215, July-Sept. 2017. tab, graf. Idioma: en. Resumo: Abstract Background Imatinib mesylate has revolutionized the treatment of chronic myeloid leukemia leading to significant reductions of BCR-ABL1 transcript levels in peripheral blood. Objective To evaluate the response to imatinib mesylate treatment (400 mg/day) in Brazilian patients in the chronic phase of chronic myeloid leukemia monitored by quantitative real time polymerase chain reaction. Methods Between October 2002 and October 2010, 3169 peripheral blood samples were collected from 1403 patients from 3 to 5 months, 6 to 11 months, 12 to 17 months, 18 to 23 months and ≥24 months after beginning imatinib treatment. Eighty-two patients had samples available and analyzed for all time intervals. BCR-ABL1 quantification was performed by quantitative real time polymerase chain reaction using the ABL1 gene as the control. Results of the BCR-ABL1 ratio as a percentage were reported by the international scale (IS) using the laboratory conversion factor (0.51). Results In the first interval, 80.8% of patients achieved the optimal response (BCR-ABL1 IS ≤ 10%). In the second period, 69.1% achieved optimal response (BCR-ABL1 IS ≤ 1%) and, between 12 and 17 months, 47.3% achieved major molecular response (BCR-ABL1 IS ≤ 0.1%). Conclusions The results of this retrospective study show that the response to imatinib treatment (400 mg/day) of Brazilian patients in the chronic phase of chronic myeloid leukemia is within the expected profile when compared to patients reported in international prospective randomized studies. Descritores: Brasil Leucemia Mielogênica Crônica BCR-ABL Positiva Mesilato de Imatinib -Proteínas Tirosina Quinases Proteínas de Fusão bcr-abl Reação em Cadeia da Polimerase em Tempo Real Limites: Humanos Responsável: BR408.1 - Biblioteca da Faculdade de Medicina - BFM

4 / 34

LILACS

seleciona para imprimir Fotocópia Texto completo SciELO Brasil Chauffaille, Maria de Lourdes L. F Velloso, Elvira Deolinda Rodrigues Pereira Simöes, Belinda Pinto Rego, Eduardo Magalhäes Texto completo Texto completo

Id: biblio-898954 Autor: Silva, Fernanda Borges da; Machado-Neto, João Agostinho; Koury, Luisa Corrêa de Araujo; Bertini, Virginia Helena Leira Lipoli; Ratis, Cristina Alonso; Chauffaille, Maria de Lourdes Lopes Ferrari; Velloso, Elvira Deolinda Rodrigues Pereira; Simões, Belinda Pinto; Rego, Eduardo Magalhães; Traina, Fabiola. Título: Acute myeloid leukemia with e1a2 BCR-ABL1 fusion gene: two cases with peculiar molecular and clinical presentations Fonte: Rev. bras. hematol. hemoter;39(4):379-384, Oct.-Dec. 2017. ilus. Idioma: en. Descritores: Leucemia Mieloide Aguda Proteínas de Fusão bcr-abl Limites: Humanos Masculino Feminino Adulto Idoso de 80 Anos ou mais Tipo de Publ: Relatos de Casos Responsável: BR408.1 - Biblioteca da Faculdade de Medicina - BFM

5 / 34

LILACS

seleciona para imprimir Fotocópia Texto completo SciELO Brasil Texto completo Texto completo

Id: lil-681971 Autor: Reis, Samuel Roosevelt Campos dos; Quixada, Acy Telles de Souza; Nunes, Sammara Tavares; Cid, Danielle Maria Camelo; Souza, Jacqueline Holanda de; Costa, Clara Maria Bastos Eloy da; Silveira, Carolina Bizelli; Cid, David Antonio Camelo; Oliveira, Mariana Fatima Cabral de. Título: Adherence to treatment with imatinib in chronic myeloid leukemia: a study of the first decade of responses obtained at a Brazilian hospital Fonte: Rev. bras. hematol. hemoter;35(3):174-179, jun. 2013. tab, graf. Idioma: en. Resumo: Objetive: The aim of this study was to identify the reasons for failure in adherence to imatinib mesylate treatment in chronic myeloid leukemia. Methods: A retrospective review was performed of 100 non-electronic records of patients with Ph+ chronic myeloid leukemia treated with imatinib mesylate. The study period was from January 2001 to January2011. Data were analyzed by Chi-Square and Correspondence analysis using the Statistical Analysis System software package. Results: At the beginning of treatment 41% of patients were in advanced stages of the disease. The unavailability of the drug (44.8%) and myelotoxicity (25.7%) were the most frequent reasons for interruption. The adherence rate was < 90% in 47% of the cases. The low adherence influenced the cytogenetic response (p-value = 0.020) and molecular response (p-value = 0.001). Very high adherence (> 95%) induced complete cytogenetic response, major cytogenetic response and major molecular response. Conclusion: The population of this study obtained lower-than-expected therapeutic responses compared to other studies. . Descritores: Piperazinas/uso terapêutico Leucemia Mielogênica Crônica BCR-ABL Positiva Leucemia Mieloide Proteínas de Fusão bcr-abl Resultado do Tratamento Adesão à Medicação Limites: Humanos Masculino Feminino Responsável: BR408.1 - Biblioteca da Faculdade de Medicina - BFM

6 / 34

LILACS

seleciona para imprimir Fotocópia Texto completo

Id: lil-797310 Autor: Amaru Calzada, Ariel; Masias, Jose; Ustarez, Eduardo; Choque, German; Peñaloza, Rosario; Mansilla, Silvia; Amaru, Ricardo. Título: Frecuencia de transcritos BCR/ABL p210 en 272 pacientes con leucemia mieloide crónica (LMC) en Bolivia / Frequency of p210 BCR-ABL transcripts in 272 Bolivian patients with chronic myeloid leukemia (CML) Fonte: Rev. méd. (La Paz);22(1):13-19, 2016. ilus. Idioma: es. Resumo: INTRODUCCIÓN: existen dos formas principales del gen de fusión BCR/ABL, que involucra al exón 2 del gen ABL y a diferentes exones del gen BCR; los transcritos b2a2 o b3a2 codifican a la proteína p210, mientras que, el transcrito e1a2 codifica a la proteína p190. En Bolivia, no existe información sobre la frecuencia de estas isoformas (BCR/ABL quimérico) en pacientes con leucemia mieloide crónica (LMC). Objetivo.- Determinar la frecuencia de co-expresión de los transcritos p210 en pacientes con LMC de Bolivia. MATERIAL Y MÉTODO: se estudió 272 pacientes diagnosticados con LMC, entre julio del 1999 a agosto del 2015. Se realizó pruebas de RT-PCR (reverse transcriptase polymerase chain reaction) en muestras de médula ósea y sangre periférica de pacientes adultos y pediátricos con diagnóstico de LMC, positivos para algún tipo de reordenamiento BCR/ABL. RESULTADOS: la expresión del transcrito b2a2 se encontró en 96 pacientes (35,3%), el trascrito b3a2 en 154 casos (56,6%) y ambos transcritos en 22 pacientes (8,1%). Se realizó análisis de supervivencia, donde se observó que a los 5 años la tasa de sobrevida fue 64%; y la sobrevida libre de progresión 42%. También se observó que el tipo de transcrito no influye en la sobrevida total ni en la sobrevida libre de enfermedad. CONCLUSIÓN: se evidenció que no existen diferencias significativas de la expresión de los diferentes transcritos BCR/ABL de los pacientes estudiados en relación a otros estudios reportados. There are two main forms of BCR/ABL fusion gene, involving exon 2 of ABL gene and different exons of the BCR gene, the transcripts b2a2 or b3a2 code for a p210 protein, and the transcript e1a2 code a p190 protein. In Bolivia, there is no information about the frequency of these isoforms of chimeric gene BCR/ABL in chronic myeloid leukemia (CML). The present study was designed to determine the frequency of co-expression of p210 transcripts in 272 patients with CML. It was conducted reverse transcriptase polymerase chain reaction (RT-PCR) tests in samples of bone marrow and peripheral blood of adult and pediatric patients with CML diagnosis, positive for some kind of BCR/ABL rearrangement. The transcript b2a2 was found in 96 (35,3%) patients; and b3a2 transcript in 154 (56.6%) cases; whereas, in 22 (8.1%) patients both transcripts were detected. Survival analysis was performed, it was observed that to 5 years the overall survival (OS) was 64%, and the progression free survival (PFS) was 42%. It was also observed that the type of transcript does not affect OS and PFS. Statistical analysis of our study, displayed no significant differences in the expression of different transcripts BCR/ABL of the Bolivian population, in relation to studies reported in other populations. Descritores: Leucemia Mielogênica Crônica BCR-ABL Positiva Proteínas de Fusão bcr-abl Responsável: BO138.1 - Biblioteca Central

7 / 34

LILACS

seleciona para imprimir Fotocópia Texto completo SciELO Brasil Texto completo

Id: lil-753967 Autor: Ribeiro, Beatriz Felicio; Miranda, Eliana C.M.; Albuquerque, Dulcinéia Martins de; Delamain, Márcia T.; Oliveira-Duarte, Gislaine; Almeida, Maria Helena; Vergílio, Bruna; Silveira, Rosana Antunes da; Oliveira-Duarte, Vagner; Lorand-Metze, Irene; Souza, Carmino A. De; Pagnano, Katia B.B.. Título: Treatment with dasatinib or nilotinib in chronic myeloid leukemia patients who failed to respond to two previously administered tyrosine kinase inhibitors - a single center experience Fonte: Clinics;70(8):550-555, 08/2015. tab, graf. Idioma: en. Resumo: OBJECTIVE: To evaluate hematological, cytogenetic and molecular responses as well as the overall, progression-free and event-free survivals of chronic myeloid leukemia patients treated with a third tyrosine kinase inhibitor after failing to respond to imatinib and nilotinib/dasatinib. METHODS: Bone marrow karyotyping and real-time quantitative polymerase chain reaction were performed at baseline and at 3, 6, 12 and 18 months after the initiation of treatment with a third tyrosine kinase inhibitor. Hematologic, cytogenetic and molecular responses were defined according to the European LeukemiaNet recommendations. BCR-ABL1 mutations were analyzed by Sanger sequencing. RESULTS: We evaluated 25 chronic myeloid leukemia patients who had been previously treated with imatinib and a second tyrosine kinase inhibitor. Nine patients were switched to dasatinib, and 16 patients were switched to nilotinib as a third-line therapy. Of the chronic phase patients (n=18), 89% achieved a complete hematologic response, 13% achieved a complete cytogenetic response and 24% achieved a major molecular response. The following BCR-ABL1 mutations were detected in 6/14 (43%) chronic phase patients: E255V, Y253H, M244V, F317L (2) and F359V. M351T mutation was found in one patient in the accelerated phase of the disease. The five-year overall, progression-free and event-free survivals were 86, 54 and 22% (p<0.0001), respectively, for chronic phase patients and 66%, 66% and 0% (p<0.0001), respectively, for accelerated phase patients. All blast crisis patients died within 6 months of treatment. Fifty-six percent of the chronic phase patients lost their hematologic response within a median of 23 months. CONCLUSIONS: Although the responses achieved by the third tyrosine kinase inhibitor were not sustainable, a third tyrosine kinase inhibitor may be an option for improving patient status until a donor becomes available for transplant. Because the long-term outcome ... Descritores: Antineoplásicos/uso terapêutico Dasatinibe/uso terapêutico Resistência a Medicamentos/efeitos dos fármacos Leucemia Mielogênica Crônica BCR-ABL Positiva/tratamento farmacológico Inibidores de Proteínas Quinases/uso terapêutico Proteínas Tirosina Quinases/antagonistas & inibidores Pirimidinas/uso terapêutico -Exame de Medula Óssea Intervalo Livre de Doença Proteínas de Fusão bcr-abl/genética Estimativa de Kaplan-Meier Cariotipagem Leucemia Mielogênica Crônica BCR-ABL Positiva/genética Mutação Reação em Cadeia da Polimerase em Tempo Real Fatores de Tempo Resultado do Tratamento Limites: Adolescente Adulto Idoso Feminino Humanos Masculino Pessoa de Meia-Idade Adulto Jovem Tipo de Publ: Estudo de Avaliação Research Support, Non-U.S. Gov't Responsável: BR1.1 - BIREME

8 / 34

LILACS

seleciona para imprimir Fotocópia Texto completo SciELO Brasil Texto completo

Id: lil-727664 Autor: Xia, D.Y.; Liu, L.; Hao, M.W.; Liu, Q.; Chen, R.A.; Liang, Y.M.. Título: A combination of STI571 and BCR-ABL1 siRNA with overexpressed p15INK4B induced enhanced proliferation inhibition and apoptosis in chronic myeloid leukemia Fonte: Braz. j. med. biol. res = Rev. bras. pesqui. méd. biol;47(12):1096-1101, 12/2014. graf. Idioma: en. Resumo: p15INK4B, a cyclin-dependent kinase inhibitor, has been recognized as a tumor suppressor. Loss of or methylation of the p15INK4B gene in chronic myeloid leukemia (CML) cells enhances myeloid progenitor formation from common myeloid progenitors. Therefore, we examined the effects of overexpressed p15INK4B on proliferation and apoptosis of CML cells. Overexpression of p15INK4B inhibited the growth of K562 cells by downregulation of cyclin-dependent kinase 4 (CDK4) and cyclin D1 expression. Overexpression of p15INK4B also induced apoptosis of K562 cells by upregulating Bax expression and downregulating Bcl-2 expression. Overexpression of p15INK4B together with STI571 (imatinib) or BCR-ABL1 small interfering RNA (siRNA) also enhanced growth inhibition and apoptosis induction of K562 cells. The enhanced effect was also mediated by reduction of cyclin D1 and CDK4 and regulation of Bax and Bcl-2. In conclusion, our study may provide new insights into the role of p15INK4B in CML and a potential therapeutic target for overcoming tyrosine kinase inhibitor resistance in CML. Descritores: Apoptose/efeitos dos fármacos Benzamidas/farmacologia Proliferação de Células/efeitos dos fármacos /metabolismo CYCLIN-DEPENDENT KINASE INHIBITOR PABNORMALITIES, DRUG-INDUCED/metabolismo Proteínas de Fusão bcr-abl/metabolismo Leucemia Mielogênica Crônica BCR-ABL Positiva/tratamento farmacológico Piperazinas/farmacologia Pirimidinas/farmacologia RNA Interferente Pequeno/farmacologia -Antineoplásicos/farmacologia Benzamidas/metabolismo Ciclina D1/efeitos dos fármacos Ciclina D1/metabolismo /efeitos dos fármacos CYCLIN-DEPENDENT KINASE ABBREVIATIONS AS TOPIC/efeitos dos fármacos /metabolismo CYCLIN-DEPENDENT KINASE ABBREVIATIONS AS TOPIC/metabolismo /genética CYCLIN-DEPENDENT KINASE INHIBITOR PABNORMALITIES, DRUG-INDUCED/genética Combinação de Medicamentos Resistencia a Medicamentos Antineoplásicos Regulação para Baixo/efeitos dos fármacos Proteínas de Fusão bcr-abl/antagonistas & inibidores Proteínas de Fusão bcr-abl/genética Expressão Gênica/genética KAMDINOCILLIN PIVOXIL CELLS Leucemia Mielogênica Crônica BCR-ABL Positiva/metabolismo Piperazinas/metabolismo Inibidores de Proteínas Quinases/farmacologia /efeitos dos fármacos PROTO-ONCOGENE PROTEINS C-BCL-TEMEFOS/efeitos dos fármacos /metabolismo PROTO-ONCOGENE PROTEINS C-BCL-TEMEFOS/metabolismo Pirimidinas/metabolismo /efeitos dos fármacos BCL-TEMEFOS-ASSOCIATED X PROTEIN/efeitos dos fármacos Limites: Humanos Responsável: BR1.1 - BIREME

9 / 34

LILACS

seleciona para imprimir Fotocópia Texto completo SciELO Brasil Texto completo

Id: lil-725683 Autor: Azevedo, Ilana de França; Silva Júnior, Rui Milton Patrício da; Vasconcelos, Audrey Violeta Martins de; Neves, Washington Batista das; Melo, Fárida Coeli de Barros Correia; Melo, Raul Antônio Morais. Título: Frequency of p190 and p210 BCR-ABL rearrangements and survival in Brazilian adult patients with acute lymphoblastic leukemia Fonte: Rev. bras. hematol. hemoter;36(5):351-355, Sep-Oct/2014. tab, graf. Idioma: en. Projeto: Fundação de Amparo à Ciência e Tecnologia do Estado de Pernambuco. Resumo: Objective: This study investigated the occurrence of the p190 and p210 break point clusterregion-Abelson (BCR-ABL) rearrangements in adults with acute lymphoblastic leukemia and possible associations with clinical and laboratory characteristics and survival. Methods: Forty-one over 18-year-old patients with acute lymphoblastic leukemia of both genders followed-up between January 2008 and May 2012 were included in this study. Clinical and laboratory data were obtained from the medical charts of the patients. Reverse transcription polymerase chain reaction (RT-PCR) using specific primers was employed to identify molecular rearrangements. Results: At diagnosis, the median age was 33 years, and there was a predominance of males (61%). The most common immunophenotype was B lineage (76%). BCR-ABL rearrangements was detected in 14 (34%) patients with the following distribution: p190 (28%), p210 (50%) and double positive (22%). Overall survival of patients with a mean/median of 331/246 days of follow up was 39%, respectively, negative BCR-ABL (44%) and positive BCR-ABL (28%). Conclusion: These results confirm the high frequency of BCR-ABL rearrangements and the low survival rate of adult Brazilian patients with acute lymphoblastic leukemia... Descritores: Adulto Proteínas de Fusão bcr-abl Leucemia Aguda Bifenotípica Análise de Sobrevida Limites: Humanos Adulto Responsável: BR408.1 - Biblioteca da Faculdade de Medicina - BFM

10 / 34

LILACS

seleciona para imprimir Fotocópia Texto completo SciELO Brasil Texto completo

Id: lil-703702 Autor: Almeida, Maria Helena de; Fogliatto, Laura; Couto, Dulce. Título: Importance of adherence to BCR-ABL tyrosine-kinase inhibitors in the treatment of chronic myeloid leukemia Fonte: Rev. bras. hematol. hemoter;36(1):54-59, Jan-Feb/2014. Idioma: en. Resumo: Treatment of chronic myeloid leukemia with BCR-ABL tyrosine kinase inhibitors requires full adherence in order to maximize the likelihood of achieving optimal responses, and to minimize healthcare costs. In this article, we review some of the methods available for assessing compliance, the main consequences of nonadherence on treatment outcomes, major factors commonly associated with poor compliance, a few successful measures for improving adherence and the most accepted recommendations for proactively managing adverse events. Descritores: Proteínas de Fusão bcr-abl Leucemia Mielogênica Crônica BCR-ABL Positiva Proteínas Tirosina Quinases Limites: Humanos Tipo de Publ: Revisão Responsável: BR408.1 - Biblioteca da Faculdade de Medicina - BFM

---

página 1 de 4

ir para página

Refinar a pesquisa

Base de dados : LILACSCidSaudePAHOREPIDISCADESASTRESADOLECBBOBDENFHomeoIndexMedCaribWHOLISIBECS

Formulário avançado

		Pesquisar	no campo
1			PalavrasDescritor de assuntoLimitesAutorPalavras do títuloRevistaAssunto de RevistaMonografia em SérieAutor pessoal normalizadoAutor institucionalPalavras do resumoTipo de publicaçãoConferênciaTipo de literaturaNível bibliográficoIdiomaIdentificador únicoPaís, ano de publicaçãoMês de entradaSuporte EletrônicoCategoria DeCSCategoria DeCS explodidaPais de AfiliaçãoAfiliaçãoRegistro de Ensaios Clínicos
2	and or and not		PalavrasDescritor de assuntoLimitesAutorPalavras do títuloRevistaAssunto de RevistaMonografia em SérieAutor pessoal normalizadoAutor institucionalPalavras do resumoTipo de publicaçãoConferênciaTipo de literaturaNível bibliográficoIdiomaIdentificador únicoPaís, ano de publicaçãoMês de entradaSuporte EletrônicoCategoria DeCSCategoria DeCS explodidaPais de AfiliaçãoAfiliaçãoRegistro de Ensaios Clínicos
3	and or and not		PalavrasDescritor de assuntoLimitesAutorPalavras do títuloRevistaAssunto de RevistaMonografia em SérieAutor pessoal normalizadoAutor institucionalPalavras do resumoTipo de publicaçãoConferênciaTipo de literaturaNível bibliográficoIdiomaIdentificador únicoPaís, ano de publicaçãoMês de entradaSuporte EletrônicoCategoria DeCSCategoria DeCS explodidaPais de AfiliaçãoAfiliaçãoRegistro de Ensaios Clínicos

Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde